Theriva Biologics, Inc. (TOVX)

USD 1.17

(-1.68%)

Total Debt Summary of Theriva Biologics, Inc.

  • Theriva Biologics, Inc.'s latest annual total debt in 2023 was 2.15 Million USD , up 28.14% from previous year.
  • Theriva Biologics, Inc.'s latest quarterly total debt in 2024 Q2 was 1.83 Million USD , down -9.32% from previous quarter.
  • Theriva Biologics, Inc. reported annual total debt of 1.68 Million USD in 2022, up 10.09% from previous year.
  • Theriva Biologics, Inc. reported annual total debt of 1.52 Million USD in 2021, up 222.83% from previous year.
  • Theriva Biologics, Inc. reported quarterly total debt of 2.01 Million USD for 2024 Q1, down -6.31% from previous quarter.
  • Theriva Biologics, Inc. reported quarterly total debt of 2.15 Million USD for 2023 Q4, down -3.06% from previous quarter.

Annual Total Debt Chart of Theriva Biologics, Inc. (2023 - 1993)

Historical Annual Total Debt of Theriva Biologics, Inc. (2023 - 1993)

Year Total Debt Total Debt Growth
2023 2.15 Million USD 28.14%
2022 1.68 Million USD 10.09%
2021 1.52 Million USD 222.83%
2020 473 Thousand USD -34.49%
2019 722 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD -100.0%
2010 24.4 Thousand USD -18.1%
2009 29.79 Thousand USD 0.0%
2008 - USD -100.0%
2007 900 Thousand USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%
2002 11.5 Million USD 27.78%
2001 9 Million USD 350.0%
2000 2 Million USD 0.0%
1999 2 Million USD 81.82%
1998 1.1 Million USD -31.25%
1997 1.6 Million USD 0.0%
1996 - USD -100.0%
1995 200 Thousand USD 0.0%
1994 - USD 0.0%
1993 - USD 0.0%

Peer Total Debt Comparison of Theriva Biologics, Inc.

Name Total Debt Total Debt Difference
ADC Therapeutics SA 124.37 Million USD 98.268%
Alto Neuroscience, Inc. 151.46 Million USD 98.578%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 30.87 Million USD 93.024%
Ginkgo Bioworks Holdings, Inc. 241.76 Million USD 99.109%
Nuvation Bio Inc. 4 Million USD 46.244%
Nuvation Bio Inc. 4 Million USD 46.244%
Arcus Biosciences, Inc. 11 Million USD 80.418%
Zymeworks Inc. 26.72 Million USD 91.939%